Insider · CIK 0001658544
Paul Edward Kelly
Files at RLMD (RELMADA THERAPEUTICS, INC.). First filing Sep 11, 2024, latest Nov 6, 2025.
In brief
Paul Edward Kelly files SEC Form 4 as COO and director at RLMD (RELMADA THERAPEUTICS, INC.). Since Sep 11, 2024, Paul Edward Kelly has reported 3 open-market buys worth $349k and 0 open-market sells worth $0, the latest filed on Nov 6, 2025.
A track record needs three past buys with six months of prices behind them; Paul Edward Kelly has 2, so none is measured yet.
The newest scored trade: bought $198k of RLMD on Nov 5, 2025, filed Nov 6, 2025, scored 57 (moderate). In the last 12 months: 1 buy worth $198k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RLMD: RELMADA THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | RELMADA THERAPEUTICS, INC. | $198k 90,000 shares | +22% | +896% from low-26% from high | |
| 62Notable | RELMADA THERAPEUTICS, INC. | $86k 200,000 shares | +94% | +83% from low-87% from high | |
| 49Moderate | RELMADA THERAPEUTICS, INC. | $65k 25,000 shares | +13% | +21% from low-59% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
| Nov 5, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +90,000 | $2.20 | $198k | 502,295 | Nov 6, 2025 |
| Jun 26, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 30, 2025 |
| May 16, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +200,000 | $0.43 | $86k | 412,295 | May 20, 2025 |
| Sep 9, 2024 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +25,000 | $2.59 | $65k | 212,295 | Sep 11, 2024 |
| May 24, 2024 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +43,700 | $0.00 | $0 | 109,372 | May 29, 2024 |
| May 24, 2024 | RLMD RELMADA THERAPEUTICS, INC. | JOther Stock Option (right to buy)derivative | -43,700 | $0.00 | $0 | 65,672 | May 29, 2024 |
| Dec 15, 2023 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +65,672 | $0.00 | $0 | 65,672 | Dec 19, 2023 |
Questions about Paul Edward Kelly
Answered from the filings on this page, as of the latest one.
Is Paul Edward Kelly buying or selling?
In the last 12 months Paul Edward Kelly reported 1 open-market buy worth $198k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $198k of RLMD on Nov 5, 2025. Grants, option exercises and tax withholding are not counted.
How did Paul Edward Kelly's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul Edward Kelly has 2.
Where does Paul Edward Kelly file Form 4?
Paul Edward Kelly has filed Form 4 at RLMD (RELMADA THERAPEUTICS, INC.) as COO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.